{
    "clinical_study": {
        "@rank": "131189", 
        "arm_group": [
            {
                "arm_group_label": "DLBS1449, 1x75 mg", 
                "arm_group_type": "Experimental", 
                "description": "DLBS1449 softcapsule 1x75 mg daily, taken every day along the study period."
            }, 
            {
                "arm_group_label": "DLBS1449, 1x150 mg", 
                "arm_group_type": "Experimental", 
                "description": "DLBS1449 softcapsule 1x150 mg (2 softcapsules 75 mg) daily, taken every day along the study period"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo once daily, taken every day along the study period"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a parallel, 3-arm, randomized, prospective, placebo-controlled, and double-blind\n      clinical study for eight weeks of therapy to investigate the clinical efficacy of DLBS1449\n      in elevating high density lipoprotein (HDL) cholesterol in diabetic patients. The hypothesis\n      of interest for the study is: the administration of DLBS1449 will elevate HDL-cholesterol\n      level from baseline to the end of study significantly higher than the elevation resulted by\n      placebo. In addition, the administration of DLBS1449 at the dose of 150 mg daily will\n      provide a significantly better response than that of the lower dose (DLBS1449 75 mg daily)."
        }, 
        "brief_title": "DLBS1449 in Diabetic Patients With Low HDL", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetic Patients", 
            "Low HDL-cholesterol (< 35 mg/dL)", 
            "Lifestyle Intervention for at Least 1 Month"
        ], 
        "detailed_description": {
            "textblock": "There will be three groups of treatment by dosage regimen in this study. Eligible subjects\n      will be randomized to receive any of the following regimens: 1) DLBS1449 at a dose of 1 x 75\n      mg daily, or 2) DLBS1449 at a dose of 1 x 150 mg (two capsules of DLBS1449 75 mg) daily; or\n      3) placebo, once daily. Study medication should be administered once daily, in the evening\n      with meal, for eight weeks. Clinical and laboratory examinations to evaluate investigational\n      drug's efficacy and safety will be performed at baseline and at interval of four weeks over\n      8-week course of therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18 - 70 years.\n\n          -  Have been diagnosed diabetes mellitus and being treated with lifestyle intervention\n             for at least 1 month prior to screening, with or without antidiabetic agents.\n\n          -  HDL-cholesterol level of < 35 mg/dL.\n\n          -  Triglycerides level of < 200 mg/dL.\n\n          -  Adequate liver and renal function.\n\n          -  statin and/or fenofibrate therapy should have been being regularly taken for >=3\n             months at stable dose (ONLY for subjects currently under statin and/or fenofibrate\n             therapy).\n\n          -  Able to take oral medication.\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding women or willing to be pregnant.\n\n          -  Symptomatic congestive heart failure, unstable angina pectoris, or cardiac\n             arrhythmia.\n\n          -  Uncontrolled hypertension (SBP > 160 mmHg and/or DBP > 100 mmHg).\n\n          -  Any other disease state, including chronic/acute systemic infections, uncontrolled\n             illnesses or other chronic diseases, which judged by the investigator, could\n             interfere with trial participation or trial evaluation.\n\n          -  Concurrent treatment with systemic corticosteroids or herbal (alternative) medicines.\n\n          -  Known allergic or hypersensitive to drugs contain similar active substance with the\n             study medication.\n\n          -  Participation in any other clinical studies within 30 days prior to screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "135", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01972477", 
            "org_study_id": "DLBS1449-0111"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "DLBS1449, 1x75 mg", 
                    "DLBS1449, 1x150 mg"
                ], 
                "description": "Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.", 
                "intervention_name": "DLBS1449", 
                "intervention_type": "Drug", 
                "other_name": "Forhidrol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo will be given every day for 8 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "DLBS1449", 
            "diabetes mellitus", 
            "HDL-cholesterol"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "location": {
            "contact": {
                "last_name": "Askandar Tjokroprawiro, Prof, SpPD, K-EMD, FINASIM, MD", 
                "phone": "+6231 5023866, +62811 316449"
            }, 
            "contact_backup": {
                "last_name": "Sri Murtiwi, SpPD, K-EMD, FINASIM, MD", 
                "phone": "+6231 5023866, +62811 345906"
            }, 
            "facility": {
                "address": {
                    "city": "Surabaya", 
                    "country": "Indonesia", 
                    "state": "East Java"
                }, 
                "name": "Surabaya Diabetes and Nutrition Center, Dr. Soetomo Hospital; Pusat Diagnostik Terpadu Building 7th Floor"
            }, 
            "investigator": [
                {
                    "last_name": "Sri Murtiwi, SpPD, K-EMD, FINASIM, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Agung Pranoto, Prof, SpPD, K-EMD, FINASIM, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ari Sutjahjo, SpPD, K-EMD, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Soebagijo Adi, SpPD, K-EMD, FINASIM, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sony Wibisono, SpPD, K-EMD, FINASIM, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jongky H Prayitno, SpPD, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hermina Novida, SpPD, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hermawan Susanto, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Effect of DLBS1449 in Diabetic Patients With Low HDL-Cholesterol - Double Blind Comparative Study With Placebo", 
        "overall_contact": {
            "last_name": "Askandar Tjokroprawiro, Prof, SpPD, K-EMD, FINASIM, MD", 
            "phone": "+6231 5023866, +62811 316449"
        }, 
        "overall_contact_backup": {
            "last_name": "Sri Murtiwi, SpPD, K-EMD, FINASIM, MD", 
            "phone": "+6231 5023866, +62811 345906"
        }, 
        "overall_official": {
            "affiliation": "Surabaya Diabetes and Nutrition Center, Dr. Soetomo Hospital", 
            "last_name": "Askandar Tjokroprawiro, Prof, SpPD, K-EMD, FINASIM, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent change in HDL-cholesterol level", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01972477"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent change in HDL-cholesterol level", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "measure": "Percent change in LDL-cholesterol level", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "measure": "Percent change in sd LDL-cholesterol level", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "measure": "Percent change in triglycerides level", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "measure": "Percent change in total cholesterol level", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "measure": "Change in Apo-A1", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "measure": "Change in Apo-B", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "Response rate is defined as percentage of subjects with HDL-cholesterol >= 40 mg/dL after 8 weeks of treatment.", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Change in A1c level", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Vital signs measurements include: blood pressure, heart rate, and respiratory rate.", 
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "Routine hematology measurements include: hemoglobin, hematocrit, RBC, WBC, differentiation of WBC, and platelet count.", 
                "measure": "Routine hematology", 
                "safety_issue": "Yes", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "Liver function measurements include: serum ALT, serum AST, gamma-GT, and alkaline phosphatase.", 
                "measure": "Liver function", 
                "safety_issue": "Yes", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "Renal function measurement includes: serum creatinine.", 
                "measure": "Renal function", 
                "safety_issue": "Yes", 
                "time_frame": "4 and 8 weeks"
            }, 
            {
                "description": "The interpretation of ECG result will be recorded. Any worsened changes from baseline condition will be counted as adverse events.", 
                "measure": "Electrocardiography (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Adverse event will be observed and recorded during the study period.", 
                "measure": "Adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "1-8 weeks"
            }
        ], 
        "source": "Dexa Medica Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dexa Medica Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}